Skip to main content
Clinical Trials/IRCT2016082129403N2
IRCT2016082129403N2
Completed
Phase 2

Study of efficacy and safety of neoadjuvant chemotherapy with CAPOX regimen and neoadjuvant chemoradiation in complete pathologic responce in locally advanced rectal cancer

Vice chancellor for research, Shiraz University of Medical Sciences0 sites40 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Rectal cancer.
Sponsor
Vice chancellor for research, Shiraz University of Medical Sciences
Enrollment
40
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Vice chancellor for research, Shiraz University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • pathologically proved adenocarcinoma of the rectum; age 18 years old or older; clinically staged II\-III tumor by MRI and/or EUS; ECOG performance status of 0 or 1; no previous history of malignancy, pelvic radiotherapy or chemotherapy; normal or adequate bone marrow reserve; normal or adequate liver and kidney function. Exclusion criteria: patients with distant metastatic disease; prior history of radiation therapy to the pelvis; prior history of chemotherapy for rectal cancer; active connective tissue disease such as scleroderma or Crohn's disease; uncontrolled diabetes mellitus, hypertension or recent cardiovascular disease; significant neuropathy; any previous or recent hypersensitivity or contraindication for chemotherapy agents.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials